双嘧达莫能特异性减少血小板衍生生长因子从血小板中的释放。

Dipyridamole specifically decreases platelet-derived growth factor release from platelets.

作者信息

Takehara K, Igarashi A, Ishibashi Y

机构信息

Department of Dermatology, University of Tokyo Branch Hospital, Japan.

出版信息

Pharmacology. 1990;40(3):150-6. doi: 10.1159/000138653.

DOI:10.1159/000138653

PMID:2139727

Abstract

We previously reported that dipyridamole decreased platelet-derived growth factor (PDGF) levels in human serum by lowering the release of PDGF during blood clotting. In this study, we have shown that this effect is specific for dipyridamole, and is not shown in other anti-platelet drugs such as aspirin, trapidil or ticlopidine. In addition, dipyridamole has been shown to decrease the PDGF level selectively, but not the levels of other factors from alpha-granules in platelets (beta-thromboglobulin and platelet factor IV). These data indicate that dipyridamole may be an effective drug for preventing PDGF-related disorders.

摘要

我们之前报道过，双嘧达莫通过降低血液凝固过程中血小板衍生生长因子（PDGF）的释放来降低人血清中PDGF的水平。在本研究中，我们已经表明这种作用是双嘧达莫所特有的，而阿司匹林、曲匹地尔或噻氯匹定等其他抗血小板药物则没有这种作用。此外，双嘧达莫已被证明能选择性降低PDGF水平，但不会降低血小板α颗粒中其他因子（β-血小板球蛋白和血小板因子IV）的水平。这些数据表明双嘧达莫可能是预防与PDGF相关疾病的有效药物。